Oct 2016 - YProtech secures successful fundraise

YProtech have secured a successful fundraise for specialist chemical technology services company arranged by Acceleris Capital. YProtech have raised £0.25m from a syndicate including Catapult Ventures, existing shareholders and new HNW individuals. The funds are to be used to launch a high-potency facility at YProtech’s Alderley Science Park base. Tony Flinn has also been appointed to the Board as a new Non-Executive Director. To read more click here.

Sept 2016 - YProtech obtains Controlled Drugs Licence

YProtech has obtained Home Office approval under the Misuse of Drugs Act 1971 to Possess, Supply and Produce Controlled Drugs including all Schedule 1, Schedule2, Schedule 3 and Schedule 4 drugs. The licence also approves YProtech to Supply and Produce Schedule 5 drugs.

With this licence, and by following the accompanying procedures and protocols, YProtech can now carry out research projects for clients that incorporate controlled substances such as phenylethylamines. This both broadens YProtech's services offering and strengthens our capabilities.

If you have any chemistry challenges incorporating controlled substances we can provide you with a competitive proposal.

Sept 2016 - New Products: Tomaymycin (CAS 35050-55-6) and Tomaymycin DM (CAS 945490-09-5) Available

YProtech are now offering the pyrrolobenzadiazapine cytotoxin natural products Tomaymycin (CAS 35050-55-6) and Tomaymycin DM (CAS 945490-09-5). Manufactured in the UK, these toxins are available to ship directly from YProtech. Please send your enquiries to This email address is being protected from spambots. You need JavaScript enabled to view it..

July 2016 - YProtech launch range of linker products for application in the synthesis of Antibody Drug Conjugates (ADCs)

Building on successful internal projects YProtech now offers multigram quantities of enzyme cleavable linker compounds for Antibody Drug Conjugates. Visit our products page for further information.